bioprinting News
-
ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting ...
-
VIVAX BIO and 3D Bioprinting Solutions World’s First To Print Living Tissue in Space
VIVAX BIO, 3D Bioprinting Solutions biotechnology laboratory and INVITRO, a leading medical company, announced a successful completion of the first stage of the Magnetic 3D Bioprinter space experiment. On December 3, 2018, the Organ.Aut bioprinter was delivered to the ISS on board the Soyuz MS-11 manned spacecraft. For the first time on orbit, cosmonaut-researcher Oleg Kononenko printed human ...
-
Bioprinting: Poietis announces the award of a third new major European patent
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. EP3233499 entitled «Laser printing method and device for implementing said method», which covers in particular the process of bioprinting upwards, previously delivered in France, and in Europe on March 21st, 2019. As a reminder ...
By Poietis
-
3D Bioprinting Solutions and URSC Cooperation Agreement - The Development of a Bioprinter for Space Applications
3D Bioprinting Solutions, a resident company of Skolkovo Innovation Center has entered into a cooperation agreement with URSC (Unified Rocket and Space Corporation, a member of ROSCOSMOS State Corporation), aiming to create a unique bioprinter capable of magnetic biofabrication of tissue and organ constructs in zero-gravity at the International Space Station (ISS). It was signed by the URSC ...
-
McEwen Stem Cell Institute at the University Health Network (UHN) is a global leader in stem cell research and regenerative medicine
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem ...
-
Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...
By CELLINK
-
Aspect Biosystems To Present New Data At International Pancreas And Islet Transplant Association (Ipita) Congress 2021
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and ...
-
CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community
CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for ...
By Atelerix Ltd
-
CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
By CELLINK
-
VIVAX BIO, 3D Bioprinting Solutions, and partners complete the first cultured meat biofabrication experiment on board the ISS.
3D Bioprinting Solutions biotechnology laboratory, Meal Source Technologies, as well as Aleph Farms and Finless Foods, are proud to announce successful result of the joint project which involved magnetic biofabrication of bovine, mummichog and rabbit myoblast/fibroblast constructs in order to lay the groundwork for renewable protein sources for long term manned missions. Additionally, results of ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
3-D Printed Biomesh Minimizes Hernia Repair Complications
Over 400,000 surgeries are conducted every year in the US alone to treat hernias, one of the most common soft tissue injuries. However, the current standard of care is a highly in?ammatory process causing visceral adhesions and postsurgical complications. To address these complications, the team at Baylor College of Medicine recently used our REGENHU bioprinter to design a 3D printed biomesh ...
By Regenhu
-
BIOLIFE4D Becomes First U.S. Company to Successfully Demonstrate Ability to 3D Bioprint a Mini Human Heart
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. The scientific milestone was accomplished at the Company’s research facility at ...
By BIOLIFE4D
-
Aspect Biosystems to Present at 2021 Virtual Cell & Gene Meeting on the Med
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. This is the second time that the company will be presenting at this conference. The Business Development Team from Aspect ...
-
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018. BIOLIFE4D’s modified Regulation A+ offering will allow the company to ...
By BIOLIFE4D
-
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear (auricle) to be smaller than typical, misshapen, and sometimes ...
-
Poietis signs a clinical research collaboration contract with the Assistance Publique – Hôpitaux de Marseille (AP-HM) to prepare the first clinical trial of a bioprinted skin.
Poietis, leading bioprinting company, and the « Assistance Publique – Hôpitaux de Marseille » (AP-HM) announced today that they have entered into a partnership through the signature the 20th of January of a clinical research collaboration contract on a bioprinted tissue engineering product. The objective of this agreement is to carry out within two years a Phase I clinical ...
By Poietis
-
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you